Trial reportBlood2011
Combination of melphalan and dexamethasone for patients with newly diagnosed POEMS syndrome.
Trial report in Blood, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 134 citations in OpenAlex.
- Treatment for POEMS (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes) syndrome.The Cochrane database of systematic reviews · 2012Pooled it
- Trial
- POEMS Syndrome: 2026 Update on Diagnosis, Risk-Stratification, and Management.American journal of hematology · 2026Review
- POEMS syndrome: diagnosis, treatments, and outcomes.Hematology. American Society of Hematology. Education Program · 2025Article
- Long-term outcomes of newly diagnosed POEMS syndrome patients who received first-line lenalidomide-based therapy.Haematologica · 2024Article
- Review
- Efficacy of bortezomib, cyclophosphamide, and dexamethasone for newly diagnosed POEMS syndrome patients.Therapeutic advances in neurological disorders · 2024Article
- Castleman disease variant of POEMS syndrome without M protein: a case report.Frontiers in oncology · 2024Article
- Article
- Comprehensive Diagnosis and Management of POEMS Syndrome.HemaSphere · 2022Review
- Efficacy of novel agents in patients with nephropathy associated with POEMS syndrome.International urology and nephrology · 2022Article
- [The consensus of the diagnosis of monoclonal gammopathies of clinical significance in China (2022)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2022Article
- Article
- Update on the POEMS syndrome.Blood research · 2022Review
- Combined Therapy with Ixazomib, Lenalidomide, and Dexamethasone for Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes Syndrome.Internal medicine (Tokyo, Japan) · 2022Article
- Paraproteinemia and neuropathy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2021Review
- Treatment and outcomes of POEMS syndrome: changes in the past 20 years.Blood cancer journal · 2021Article
- Revealing serum lipidomic characteristics and potential lipid biomarkers in patients with POEMS syndrome.Journal of cellular and molecular medicine · 2021Article
- Ischemic stroke in patients with POEMS syndrome.Blood advances · 2020Article
- Endocrine Evaluation in POEMS Syndrome: A Cohort Study.Frontiers in endocrinology · 2020Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
POEMS syndrome is a rare clonal plasma cell disorder without standard treatment. Based on the efficacy and low toxicity of a combination of melphalan and dexamethasone (MDex) for light chain amyloidosis, we conducted a prospective study of MDex treatment for patients with newly diagnosed POEMS syndrome. Thirty-one patients (19 men) were enrolled and the median age at the time of diagnosis was 44 years (range, 32-68 years). All patients received 12 cycles of MDex treatment. Twenty-five patients (80.6%) achieved hematologic response including 12 (38.7%) complete remission and 13 (41.9%) partial remission. Of all 31 patients, the neurologic response rate was 100%, assessed by overall neuropathy limitation scale (ONLS). The initial neurologic response was observed in 24 patients (77.4%) at 3 months after treatment and the median time to maximal neurologic response was 12 months (range, 3-15 months). Moreover, MDex substantially improved the level of serum vascular endothelial growth factor and relieved organomegaly, extravascular volume overload, and pulmonary hypertension. Only 6 patients (19.3%) suffered from grade 3 adverse events during treatment. All patients are alive and free of neurologic relapse after the median follow-up time of 21 months. Therefore, MDex is an effective and well-tolerated treatment option for patients with newly diagnosed POEMS syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.